COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION
摘要
<p>The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti- HCV activity.</p>
